Abstract Library

#4623 [68Ga]Ga-DOTA-Exendin-4 PET/CT for the localisation of insulinoma: Results of an international, dual-centre, retrospective, open-label real-world imaging study

Introduction: Benign insulinomas are the main cause of endogenous hyperinsulinemic hypoglycaemia (EHH) in adults, with surgery as the only cure. Pancreas-preserving procedures are preferred, making precise localisation crucial. Recent studies indicate that GLP-1R imaging, such as [68Ga]Ga-DOTA-exendin-4 (68Ga-Ex4) PET/CT, outperforms conventional imaging in identifying insulinomas.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Laubner K, Schildmeijer M, Menz L, Christ E,

Keywords: GLP1-Receptor PET/CT, Insulinoma, nesidioblatosis, endogenous hyperinsulinemic hypoglycaemia, real-life data,

#4561 Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,

#4118 Adverse events after endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy in pancreatic neuroendocrine tumors: A systematic review

Introduction: Pathological analysis of pancreatic neuroendocrine tumors (pNET) is essential for predicting tumor behaviour and patient management. Although endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the established practice for retrieving tissue, fine-needle biopsy (EUS-FNB) offers possibilities for additional analyses including tumor grading. This systematic review provides a comprehensive evaluation of EUS-FNA and EUS-FNB-related adverse events in pNET.

Conference:

Presenting Author: Chen J

Authors: Chen J, Verschuur A, Abdelmonem A, Dreijerink K, Engelsman A,

Keywords: pancreatic neuroendocrine tumor, EUS-FNA, EUS-FNB, adverse events, systematic review,

#4050 PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,

#3792 Validation of a single time-point estimates of 177Lu-PRRT absorbed doses and impact on patient management for 192 therapies

Introduction: Dosimetry calculation after 177Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy (PRRT) enables to estimate radiation doses absorbed by normal organs and target lesions. Previously, we described a newly developed model to predict absorbed doses (ADs) from a single post-treatment study with good accuracy as compared to the standard multiple time-points protocol.

Conference:

Presenting Author:

Authors: Chicheportiche A, Krausz Y, Godefroy J, Gross D, Grozinsky-Glasberg S,

Keywords: PRRT, Dosimetry, SPECT/CT, Single time-point,